Gold prices have struggled to rise despite inflation pressures from the Iran war and global energy crisis, as expectations for U.S. interest rate hikes increase. Commerzbank analyst Carsten Fritsch notes that the market now expects the Federal Reserve to raise rates later this year, raising the opportunity cost of holding gold, a non-yielding asset. Consequently, Commerzbank lowered its year-end gold price forecast from $5,000 to $4,800 an ounce but still sees potential for an 8% rally if the Iran conflict eases and oil prices fall. The bank expects rates to remain steady until at least Q2 2027, supporting a longer-term gold price target of $5,200 per ounce by the end of 2027. Silver prices were also downgraded due to weaker industrial demand, with a revised year-end target of $80 an ounce.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
